Results 41 to 50 of about 285,607 (297)
Anticoagulation in pulmonary arterial hypertension: a decision analysis
Pulmonary Circulation, 2019 Systemic anticoagulation may be beneficial in pulmonary arterial hypertension, but there is no randomized clinical trial data to guide therapeutic decision making, and current guidelines do not account for patient preferences or quality of life. Decision
Arun Jose +2 more
doaj +1 more source
Pulmonary Circulation, 2021 Inhalation profiles to support use of dry powder inhalers for drug delivery in patients with pulmonary arterial hypertension have not been reported. We aimed to evaluate the inspiratory flow pattern associated with low and medium flow resistance dry ...
Mariana Faria-Urbina +4 more
doaj +1 more source
Gestational Pulmonary Arterial Hypertension [PDF]
Pulmonary Circulation, 2015 Pulmonary arterial hypertension (PAH) is a progressive disease marked by the irreversible pulmonary vascular changes of vasoconstriction, thrombosis, and proliferation of smooth muscle and endothelial cells. The untreated clinical course is characterized by progressive dyspnea and a median survival of less than 3 years.
Matthew, Moll +3 more
openaire +2 more sources
Right ventriculo–pulmonary arterial uncoupling and poor outcomes in pulmonary arterial hypertension
Pulmonary Circulation, 2020 Right ventricular function critically affects the prognosis of patients with pulmonary arterial hypertension. We aimed to analyze the prognostic value of right ventricular indices calculated using magnetic resonance imaging and right heart ...
Toshitaka Nakaya +8 more
doaj +1 more source
Pulmonary Circulation, 2022 Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability.
Mauricio Orozco‐Levi +11 more
doaj +1 more source
Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study [PDF]
, 2017 BackgroundIdiopathic and heritable pulmonary arterial hypertension form a rare but molecularly heterogeneous disease group. We aimed to measure and validate differences in plasma concentrations of proteins that are associated with survival in patients ...
Abdul-Salam +29 more
core +1 more source
Under pressure: pulmonary hypertension associated with left heart disease. [PDF]
, 2015 © ERS 2015.Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common type of PH, but its natural history is not well understood.
Farber, HW, Gibbs, S
core +2 more sources
Role of the aryl hydrocarbon receptor in Sugen 5416-induced experimental pulmonary hypertension [PDF]
, 2018 Rationale: Rats dosed with the vascular endothelial growth factor (VEGF) inhibitor Sugen 5416 (Su), placed in hypoxia then restored to normoxia has become a widely used model of pulmonary arterial hypertension (PAH).
Dean, Afshan +6 more
core +1 more source
Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension [PDF]
, 2016 BACKGROUND: Right ventricular (RV) function is a major determinant of exercise intolerance and outcome in idiopathic pulmonary arterial hypertension (IPAH). The aim of the study was to evaluate the incremental prognostic value of echocardiography of the
Badagliacca, Roberto +11 more
core +1 more source
Idiopathic pulmonary arterial hypertension [PDF]
Disease Models & Mechanisms, 2010 Despite improved understanding of the pathobiology of pulmonary arterial hypertension (PAH), it remains a severe and progressive disease, usually culminating in right heart failure, significant morbidity and early mortality. Over the last decade, some major advances have led to substantial improvements in the management of PAH.
Amy L, Firth +2 more
openaire +2 more sources